There is no confirmed drug therapy for plastic bronchitis. The study wish to test the effectiveness and safety of sirolimus (rapamycin) in patients with lymphatic plastic bronchitis.
Plastic bronchitis is a rare respiratory disorder characterized by formation of gelatinous or rigid cast of bronchial tree. Confirmed drug therapy for plastic bronchitis is lacking. Recently, part of plastic bronchitis has been found to have dysfunction of lymphatic circulation in the lung. Pulmonary lymphatic perfusion syndrome (PLPS) is regarded as a major mechanism of lymphatic plastic bronchitis. Sirolimus (rapamycin) has not been studied in plastic bronchitis, however, it has been shown effective in several lymphatic disorders, such as lymphangioleiomyomatosis, generalized lymphatic anomaly (GLA) including lymphangiomatosis, etc. We wish to test the effectiveness of sirolimus in lymphatic plastic bronchitis.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
TREATMENT
Masking
NONE
Enrollment
10
Patients will receive sirolimus for 6 months.
Peking Union Medical College Hospital
Beijing, Beijing Municipality, China
RECRUITINGchanges of pulmonary lymphatic perfusion distribution
quantitatively measured with 68Ga-NEB positron emission tomography (PET) at baseline and the end of study
Time frame: 6 months
changes of coughing score
measured by coughing VAS score (0-10) at baseline, 3 months and the end of study
Time frame: 6 months
changes of pulmonary function (FEV1, FVC)
measured by spirometry at baseline, 3 months and the end of study
Time frame: 6 months
changes of six minutes walking distance
measured by six minutes walking test at baseline, 3 months and the end of study
Time frame: 6 months
change of health-related quality of life
measure by St George Respiratory Questionnaire at baseline, 3 months and the end of study
Time frame: 6 months
changes of breathlessness score
measured by Borg scale (0-10) at baseline, 3 months and the end of study
Time frame: 6 months
Number of participants with treatment-related adverse events as assessed by CTCAE v4.0
Common Terminology Criteria for Adverse Events (CTCAE) was used to collect adverse effects at baseline and through study completion
Time frame: 6 months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.